ArticleJournal of the American Academy of Dermatology2018
Stage IV melanoma of unknown primary: A population-based study in the United States from 1973 to 2014.
Article in Journal of the American Academy of Dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06093594 (Understanding Patient Engagement Trends in Stage IV Melanoma Clinical Trials), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Understanding Patient Engagement Trends in Stage IV Melanoma Clinical Trials
Who cites it
12 citing papers in PubMed.
- Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Observational
- Clinicopathological characteristics and prognosis of melanoma: A retrospective cohort study in Xinjiang, China.PloS one · 2026Article
- Diverse radiotherapy fractionation in malignant melanoma: a case report.Frontiers in oncology · 2025Article
- An analysis of lactate dehydrogenase (LDH) levels in advanced stage IV melanoma of the skin: prognostic capabilities and demographic variability.Archives of dermatological research · 2023Article
- Melanoma Treatment: The Heart Has Skin in the Game.JACC. CardioOncology · 2022Article
- Treatment of Metastatic Melanoma at First Diagnosis: Review of the Literature.Life (Basel, Switzerland) · 2022Review
- Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy.Cancer immunology, immunotherapy : CII · 2021Article
- Metastatic melanoma of unknown origin mimicking neurofibromatosis.Radiology case reports · 2021Article
- Trend and socioeconomic disparities in survival outcome of metastatic melanoma after approval of immune checkpoint inhibitors: a population-based study.American journal of translational research · 2020Article
- Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population-based study.International journal of cancer · 2020Article
- Metastatic Melanoma of Uncertain Primary with 5-Year Durable Response after Conventional Therapy: A Case Report with Literature Review.Case reports in oncological medicine · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMelanoma of unknown primary (MUP) is incompletely described on a population level.
objectiveWe sought to characterize stage IV MUP in a population-based cancer registry.
methodsWe developed a novel search algorithm to identify cases of stage IV MUP in the Surveillance, Epidemiology, and End Results 18 registries from 1973 to 2014. Cases of stage IV melanoma of known primary (MKP) served as a comparison group. Age-standardized incidence rates, demographic characteristics, adjusted disease-specific survival, and Cox proportional hazard models were calculated for MUP and MKP.
resultsA total of 322 stage IV MUP cases and 12,796 stage IV MKP cases were identified in Surveillance, Epidemiology, and End Results 18 registries from 1973 to 2014. The incidence of stage IV MUP is increasing, particularly for patients younger than 30 years of age. In multivariate analyses, age older than 50 and a lack of surgical treatment were negative prognostic factors for stage IV MUP. Relative survival, but not 5-year adjusted disease-specific survival, was higher for stage IV MUP than for MKP. LIMITATIONS: Limitations include the retrospective study design and possible misclassification of MUP.
conclusionsThe incidence of stage IV MUP is increasing, and stage IV MUP shares similar prognostic factors with stage IV MKP, including age and surgical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.